David Standring
6Patents
4h-index
7Co-inventors
46Inventor score
Filing activity: Sep 15, 2003 → Dec 16, 2015
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7824851B2 | 2′-branched nucleosides and Flaviviridae mutation | Emerging Cross-Sectional Technologies | 54 | Expired |
| US8674085B2 | 2′-branched nucleosides and Flaviviridae mutation | Emerging Cross-Sectional Technologies | 27 | Active |
| US7186700B2 | β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | Human Necessities | 11 | Expired |
| US7928086B2 | β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | Human Necessities | 7 | Active |
| US8158606B2 | β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | Human Necessities | 4 | Active |
| US10525072B2 | 2′-branched nucleosides and flaviviridae mutation | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.